NXGL Quote, Financials, Valuation and Earnings

The Cooper Companies has a net margin of -23.57% compared to NexGel's net margin of 10.81%. NexGel's return on equity of -67.5% beat The Cooper Companies's return on equity of 5.24%.

NexGel has a consensus price target of --, signalling upside risk potential of 94.18%. On the other hand The Cooper Companies has an analysts' consensus of $107.41 which suggests that it could grow by 27.76%. Given that NexGel has higher upside potential than The Cooper Companies, analysts believe NexGel is more attractive than The Cooper Companies.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Cooper Companies has a beta of 1.022, suggesting its more volatile than the S&P 500 by 2.176%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Companies offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. NexGel pays -- of its earnings as a dividend. The Cooper Companies pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.9M, which are smaller than The Cooper Companies quarterly revenues of $964.7M. NexGel's net income of -$693K is lower than The Cooper Companies's net income of $104.3M. Notably, NexGel's price-to-earnings ratio is -- while The Cooper Companies's PE ratio is 40.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 2.82x versus 4.30x for The Cooper Companies. Usually stocks with elevated PS ratios are considered overvalued.

OrthoPediatrics has a net margin of -23.57% compared to NexGel's net margin of -30.51%. NexGel's return on equity of -67.5% beat OrthoPediatrics's return on equity of -10.25%.

NexGel has a consensus price target of --, signalling upside risk potential of 94.18%. On the other hand OrthoPediatrics has an analysts' consensus of $39.00 which suggests that it could grow by 56.88%. Given that NexGel has higher upside potential than OrthoPediatrics, analysts believe NexGel is more attractive than OrthoPediatrics.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison OrthoPediatrics has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.767%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OrthoPediatrics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. OrthoPediatrics pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.9M, which are smaller than OrthoPediatrics quarterly revenues of $52.7M. NexGel's net income of -$693K is higher than OrthoPediatrics's net income of -$16.1M. Notably, NexGel's price-to-earnings ratio is -- while OrthoPediatrics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 2.82x versus 2.80x for OrthoPediatrics. Usually stocks with elevated PS ratios are considered overvalued.

Innovative Eyewear has a net margin of -23.57% compared to NexGel's net margin of -678.5%. NexGel's return on equity of -67.5% beat Innovative Eyewear's return on equity of -113.55%.

NexGel has a consensus price target of --, signalling upside risk potential of 94.18%. On the other hand Innovative Eyewear has an analysts' consensus of -- which suggests that it could grow by 344.02%. Given that Innovative Eyewear has higher upside potential than NexGel, analysts believe Innovative Eyewear is more attractive than NexGel.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innovative Eyewear has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. Innovative Eyewear pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.9M, which are larger than Innovative Eyewear quarterly revenues of $253.6K. NexGel's net income of -$693K is higher than Innovative Eyewear's net income of -$1.7M. Notably, NexGel's price-to-earnings ratio is -- while Innovative Eyewear's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 2.82x versus 2.06x for Innovative Eyewear. Usually stocks with elevated PS ratios are considered overvalued.

Staar Surgical has a net margin of -23.57% compared to NexGel's net margin of -69.92%. NexGel's return on equity of -67.5% beat Staar Surgical's return on equity of -5.02%.

NexGel has a consensus price target of --, signalling upside risk potential of 94.18%. On the other hand Staar Surgical has an analysts' consensus of $18.67 which suggests that it could grow by 5.05%. Given that NexGel has higher upside potential than Staar Surgical, analysts believe NexGel is more attractive than Staar Surgical.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Staar Surgical has a beta of 0.660, suggesting its less volatile than the S&P 500 by 34.006%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Staar Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. Staar Surgical pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $2.9M, which are smaller than Staar Surgical quarterly revenues of $49M. NexGel's net income of -$693K is higher than Staar Surgical's net income of -$34.2M. Notably, NexGel's price-to-earnings ratio is -- while Staar Surgical's PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 2.82x versus 2.80x for Staar Surgical. Usually stocks with elevated PS ratios are considered overvalued.